만성 C형 간질환에서 Interferon 치료반응에 영향을 미치는 인자
Backgound/Aim '. Although interferon-a(IFNa) is currently the most effective antiviral agent for treating patients with chronic hepatitis C, its efficacy is not always reliable. Factors suggested to infruence outcome of IFN-a therapy for chronic hepatitis C are histological activity, level of v...
Gespeichert in:
| Veröffentlicht in: | Clinical and molecular hepatology 1996-01, Vol.2 (2), p.176 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | kor |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 2 |
| container_start_page | 176 |
| container_title | Clinical and molecular hepatology |
| container_volume | 2 |
| creator | 김연수 권소영 서동진 이창홍 Yun Soo Kim So Young Kwan Dong Jin Suh Chang Hong Lee |
| description | Backgound/Aim '. Although interferon-a(IFNa) is currently the most effective antiviral agent for treating patients with chronic hepatitis C, its efficacy is not always reliable. Factors suggested to infruence outcome of IFN-a therapy for chronic hepatitis C are histological activity, level of viremia and HCV genotype, etc. The aim of this study was to determine the relationship between several pretreatment factors and response to IFN-a therapy in patients with chronic HCV infection. Methods .' Fifty-four patients with chronic HCV infection(47 with chronic hepatitis and 7 with liver cirrhosis) who received IFN-a(2a or 2b) therapy(3 6 MU, three times a week, for 3 12 months) were included. Level of serum HCV RNA(50 patients), HCV genotype(27 patients) and IgM anti- HCV(21 patients) during pretreatment period were assayed. Results '. Overall, 19(35%) subjects achieved sustained response(SR), 12(22%) had transient response(TR) and 23(43%) did not respond (nonresponse;NR). Mean age of patients with SR, TR and NR was 46+ 10, 51+ 7.5 and 54+ 9.7 years, respectively(p |
| format | Article |
| fullrecord | <record><control><sourceid>kiss</sourceid><recordid>TN_cdi_kiss_primary_1836630</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><kiss_id>1836630</kiss_id><sourcerecordid>1836630</sourcerecordid><originalsourceid>FETCH-kiss_primary_18366303</originalsourceid><addsrcrecordid>eNpjYeA0MrIw1zUyN7LgYOAtLs5MMjAxMTc2NjQx5WQIfL28503LRgXntzOmKrza0PJmecfbmTPeTJ_wpmWOgmdeSWpRWmpRfp7Cm50zXi_ueb1hxpu5E4GyCm9mNL6dtvTN3BaF1-t3gCS7pii8mbvjzbwJPAysaYk5xam8UJqbQdrNNcTZQzc7s7g4vqAoMzexqDLe0MLYzMzYwBi_LAC_Ck2p</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>만성 C형 간질환에서 Interferon 치료반응에 영향을 미치는 인자</title><source>DOAJ Directory of Open Access Journals</source><creator>김연수 ; 권소영 ; 서동진 ; 이창홍 ; Yun Soo Kim ; So Young Kwan ; Dong Jin Suh ; Chang Hong Lee</creator><creatorcontrib>김연수 ; 권소영 ; 서동진 ; 이창홍 ; Yun Soo Kim ; So Young Kwan ; Dong Jin Suh ; Chang Hong Lee</creatorcontrib><description>Backgound/Aim '. Although interferon-a(IFNa) is currently the most effective antiviral agent for treating patients with chronic hepatitis C, its efficacy is not always reliable. Factors suggested to infruence outcome of IFN-a therapy for chronic hepatitis C are histological activity, level of viremia and HCV genotype, etc. The aim of this study was to determine the relationship between several pretreatment factors and response to IFN-a therapy in patients with chronic HCV infection. Methods .' Fifty-four patients with chronic HCV infection(47 with chronic hepatitis and 7 with liver cirrhosis) who received IFN-a(2a or 2b) therapy(3 6 MU, three times a week, for 3 12 months) were included. Level of serum HCV RNA(50 patients), HCV genotype(27 patients) and IgM anti- HCV(21 patients) during pretreatment period were assayed. Results '. Overall, 19(35%) subjects achieved sustained response(SR), 12(22%) had transient response(TR) and 23(43%) did not respond (nonresponse;NR). Mean age of patients with SR, TR and NR was 46+ 10, 51+ 7.5 and 54+ 9.7 years, respectively(p<0.05 between SR and NR). Among 30 patients with biopsy-proven chronic hepatitis, 13(43%) achieved SR;but only one(14%) in 7 patients with liver cirrhosis. Mean serum HCV RNA level(X10' copies/ml) was higher in nonresponders(7,7+ 13.0) compared with SR(2.3+ 2. 7) or TR(3.1+ 4.9), although statistically insignificant HCV genotyping in 27 patients revealed type la in 5(18.5%), 1b in 14(52%), 2a in 5(18.5%), 2b in 1(3.7%) and 4 in 2(7%), respectively. In non-1b patients, SR rate was significantly higher than 1b patients(69.2% vs. 21.4%, p=0.03). Although IgM anti-HCV was positive in 12(57%) among 21 patients studied, the positive rate and the titer of IgM anti-HCV was not significantly different in three groups. Condusion '. Our results suggest that in patients with chronic hepatitis C, infection with genotype 1b, old age, high serum HCV RNA level and the presence of cirrhosis would predict poor response to IFN therapy.</description><identifier>ISSN: 2287-2728</identifier><language>kor</language><publisher>대한간학회</publisher><subject>Chronic HCV infection ; HCV genotype ; HCV RNA level ; IgM anti - HCV ; Interferon ; Liver cirrhosis</subject><ispartof>Clinical and molecular hepatology, 1996-01, Vol.2 (2), p.176</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids></links><search><creatorcontrib>김연수</creatorcontrib><creatorcontrib>권소영</creatorcontrib><creatorcontrib>서동진</creatorcontrib><creatorcontrib>이창홍</creatorcontrib><creatorcontrib>Yun Soo Kim</creatorcontrib><creatorcontrib>So Young Kwan</creatorcontrib><creatorcontrib>Dong Jin Suh</creatorcontrib><creatorcontrib>Chang Hong Lee</creatorcontrib><title>만성 C형 간질환에서 Interferon 치료반응에 영향을 미치는 인자</title><title>Clinical and molecular hepatology</title><addtitle>Clinical and Molecular Hepatology(대한간학회지)</addtitle><description>Backgound/Aim '. Although interferon-a(IFNa) is currently the most effective antiviral agent for treating patients with chronic hepatitis C, its efficacy is not always reliable. Factors suggested to infruence outcome of IFN-a therapy for chronic hepatitis C are histological activity, level of viremia and HCV genotype, etc. The aim of this study was to determine the relationship between several pretreatment factors and response to IFN-a therapy in patients with chronic HCV infection. Methods .' Fifty-four patients with chronic HCV infection(47 with chronic hepatitis and 7 with liver cirrhosis) who received IFN-a(2a or 2b) therapy(3 6 MU, three times a week, for 3 12 months) were included. Level of serum HCV RNA(50 patients), HCV genotype(27 patients) and IgM anti- HCV(21 patients) during pretreatment period were assayed. Results '. Overall, 19(35%) subjects achieved sustained response(SR), 12(22%) had transient response(TR) and 23(43%) did not respond (nonresponse;NR). Mean age of patients with SR, TR and NR was 46+ 10, 51+ 7.5 and 54+ 9.7 years, respectively(p<0.05 between SR and NR). Among 30 patients with biopsy-proven chronic hepatitis, 13(43%) achieved SR;but only one(14%) in 7 patients with liver cirrhosis. Mean serum HCV RNA level(X10' copies/ml) was higher in nonresponders(7,7+ 13.0) compared with SR(2.3+ 2. 7) or TR(3.1+ 4.9), although statistically insignificant HCV genotyping in 27 patients revealed type la in 5(18.5%), 1b in 14(52%), 2a in 5(18.5%), 2b in 1(3.7%) and 4 in 2(7%), respectively. In non-1b patients, SR rate was significantly higher than 1b patients(69.2% vs. 21.4%, p=0.03). Although IgM anti-HCV was positive in 12(57%) among 21 patients studied, the positive rate and the titer of IgM anti-HCV was not significantly different in three groups. Condusion '. Our results suggest that in patients with chronic hepatitis C, infection with genotype 1b, old age, high serum HCV RNA level and the presence of cirrhosis would predict poor response to IFN therapy.</description><subject>Chronic HCV infection</subject><subject>HCV genotype</subject><subject>HCV RNA level</subject><subject>IgM anti - HCV</subject><subject>Interferon</subject><subject>Liver cirrhosis</subject><issn>2287-2728</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><recordid>eNpjYeA0MrIw1zUyN7LgYOAtLs5MMjAxMTc2NjQx5WQIfL28503LRgXntzOmKrza0PJmecfbmTPeTJ_wpmWOgmdeSWpRWmpRfp7Cm50zXi_ueb1hxpu5E4GyCm9mNL6dtvTN3BaF1-t3gCS7pii8mbvjzbwJPAysaYk5xam8UJqbQdrNNcTZQzc7s7g4vqAoMzexqDLe0MLYzMzYwBi_LAC_Ck2p</recordid><startdate>19960101</startdate><enddate>19960101</enddate><creator>김연수</creator><creator>권소영</creator><creator>서동진</creator><creator>이창홍</creator><creator>Yun Soo Kim</creator><creator>So Young Kwan</creator><creator>Dong Jin Suh</creator><creator>Chang Hong Lee</creator><general>대한간학회</general><scope>HZB</scope><scope>Q5X</scope></search><sort><creationdate>19960101</creationdate><title>만성 C형 간질환에서 Interferon 치료반응에 영향을 미치는 인자</title><author>김연수 ; 권소영 ; 서동진 ; 이창홍 ; Yun Soo Kim ; So Young Kwan ; Dong Jin Suh ; Chang Hong Lee</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-kiss_primary_18366303</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>kor</language><creationdate>1996</creationdate><topic>Chronic HCV infection</topic><topic>HCV genotype</topic><topic>HCV RNA level</topic><topic>IgM anti - HCV</topic><topic>Interferon</topic><topic>Liver cirrhosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>김연수</creatorcontrib><creatorcontrib>권소영</creatorcontrib><creatorcontrib>서동진</creatorcontrib><creatorcontrib>이창홍</creatorcontrib><creatorcontrib>Yun Soo Kim</creatorcontrib><creatorcontrib>So Young Kwan</creatorcontrib><creatorcontrib>Dong Jin Suh</creatorcontrib><creatorcontrib>Chang Hong Lee</creatorcontrib><collection>Korean Studies Information Service System (KISS)</collection><collection>Korean Studies Information Service System (KISS) B-Type</collection><jtitle>Clinical and molecular hepatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>김연수</au><au>권소영</au><au>서동진</au><au>이창홍</au><au>Yun Soo Kim</au><au>So Young Kwan</au><au>Dong Jin Suh</au><au>Chang Hong Lee</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>만성 C형 간질환에서 Interferon 치료반응에 영향을 미치는 인자</atitle><jtitle>Clinical and molecular hepatology</jtitle><addtitle>Clinical and Molecular Hepatology(대한간학회지)</addtitle><date>1996-01-01</date><risdate>1996</risdate><volume>2</volume><issue>2</issue><spage>176</spage><pages>176-</pages><issn>2287-2728</issn><abstract>Backgound/Aim '. Although interferon-a(IFNa) is currently the most effective antiviral agent for treating patients with chronic hepatitis C, its efficacy is not always reliable. Factors suggested to infruence outcome of IFN-a therapy for chronic hepatitis C are histological activity, level of viremia and HCV genotype, etc. The aim of this study was to determine the relationship between several pretreatment factors and response to IFN-a therapy in patients with chronic HCV infection. Methods .' Fifty-four patients with chronic HCV infection(47 with chronic hepatitis and 7 with liver cirrhosis) who received IFN-a(2a or 2b) therapy(3 6 MU, three times a week, for 3 12 months) were included. Level of serum HCV RNA(50 patients), HCV genotype(27 patients) and IgM anti- HCV(21 patients) during pretreatment period were assayed. Results '. Overall, 19(35%) subjects achieved sustained response(SR), 12(22%) had transient response(TR) and 23(43%) did not respond (nonresponse;NR). Mean age of patients with SR, TR and NR was 46+ 10, 51+ 7.5 and 54+ 9.7 years, respectively(p<0.05 between SR and NR). Among 30 patients with biopsy-proven chronic hepatitis, 13(43%) achieved SR;but only one(14%) in 7 patients with liver cirrhosis. Mean serum HCV RNA level(X10' copies/ml) was higher in nonresponders(7,7+ 13.0) compared with SR(2.3+ 2. 7) or TR(3.1+ 4.9), although statistically insignificant HCV genotyping in 27 patients revealed type la in 5(18.5%), 1b in 14(52%), 2a in 5(18.5%), 2b in 1(3.7%) and 4 in 2(7%), respectively. In non-1b patients, SR rate was significantly higher than 1b patients(69.2% vs. 21.4%, p=0.03). Although IgM anti-HCV was positive in 12(57%) among 21 patients studied, the positive rate and the titer of IgM anti-HCV was not significantly different in three groups. Condusion '. Our results suggest that in patients with chronic hepatitis C, infection with genotype 1b, old age, high serum HCV RNA level and the presence of cirrhosis would predict poor response to IFN therapy.</abstract><pub>대한간학회</pub><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2287-2728 |
| ispartof | Clinical and molecular hepatology, 1996-01, Vol.2 (2), p.176 |
| issn | 2287-2728 |
| language | kor |
| recordid | cdi_kiss_primary_1836630 |
| source | DOAJ Directory of Open Access Journals |
| subjects | Chronic HCV infection HCV genotype HCV RNA level IgM anti - HCV Interferon Liver cirrhosis |
| title | 만성 C형 간질환에서 Interferon 치료반응에 영향을 미치는 인자 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T09%3A03%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-kiss&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=%EB%A7%8C%EC%84%B1%20C%ED%98%95%20%EA%B0%84%EC%A7%88%ED%99%98%EC%97%90%EC%84%9C%20Interferon%20%EC%B9%98%EB%A3%8C%EB%B0%98%EC%9D%91%EC%97%90%20%EC%98%81%ED%96%A5%EC%9D%84%20%EB%AF%B8%EC%B9%98%EB%8A%94%20%EC%9D%B8%EC%9E%90&rft.jtitle=Clinical%20and%20molecular%20hepatology&rft.au=%EA%B9%80%EC%97%B0%EC%88%98&rft.date=1996-01-01&rft.volume=2&rft.issue=2&rft.spage=176&rft.pages=176-&rft.issn=2287-2728&rft_id=info:doi/&rft_dat=%3Ckiss%3E1836630%3C/kiss%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_kiss_id=1836630&rfr_iscdi=true |